← Back to Search

Obesity Management Training for Obesity (ROGMF-2 Trial)

Waitlist Available
Led By Marie-France Langlois, MD
Research Sponsored by Université de Sherbrooke
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
History of cancer in the last five years
Screening 3 weeks
Treatment Varies
Follow Up 18 months
Awards & highlights


This trial combined a preceptorship with a virtual learning community in order to help primary care physician teams manage obesity more effectively. The team observed significant improvements in attitudes and self-efficacy among the participants, which were maintained after one year.

Who is the study for?
This trial is for patients who have had at least four documented visits in the past two years for conditions like hypertension, type 2 diabetes, or impaired glucose tolerance. It's designed to help primary care physician teams improve their management of obesity.Check my eligibility
What is being tested?
The study tests an integrated obesity management system that includes a short training program (preceptorship) and ongoing support through a virtual community. The goal is to see if this improves weight loss and obesity care among patients with certain chronic diseases.See study design
What are the potential side effects?
Since this trial focuses on education and support systems rather than medication or medical procedures, there are no direct side effects from interventions being studied.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
I have had cancer within the last five years.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Among patients from the regular follow-up group, we aim at improving: a)the proportion of patients who have measured weight, BMI and waist circumference and b)the proportion of overweight or obese subjects who have an initial intervention planned.
Among patients from the targeted diseases group, we aim at improving: a)the proportion of subjects who have an initial intervention planned, according to the CCPGO; b)the proportion of subjects who lose at least 5% of their initial weight.
Secondary outcome measures
Among health professionals who receive the intervention (vs. those who did not), we aim at ameliorating their attitudes and perceptions towards patients and treatment effectiveness.
Among health professionals who receive the intervention (vs. those who did not), we aim at improving their perception of self-efficacy in managing obesity.
Among health professionals who receive the intervention (vs. those who did not), we aim at increasing their knowledge and expertise on obesity management and changing their practice.
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: PreceptorshipsExperimental Treatment1 Intervention
Preceptorships with e-learning
Group II: ControlActive Control1 Intervention
No intervention

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for obesity, particularly those involving educational and supportive interventions like the Preceptorship and Virtual Learning Community trial, focus on lifestyle modifications. These include dietary changes to reduce caloric intake, increased physical activity to boost energy expenditure, and behavioral therapy to modify habits contributing to weight gain. These mechanisms are essential for obesity patients as they tackle the underlying causes of obesity, support sustainable weight loss, and enhance overall health and well-being.

Find a Location

Who is running the clinical trial?

Université de SherbrookeLead Sponsor
300 Previous Clinical Trials
69,493 Total Patients Enrolled
14 Trials studying Obesity
2,222 Patients Enrolled for Obesity
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,354 Previous Clinical Trials
26,460,059 Total Patients Enrolled
56 Trials studying Obesity
9,301 Patients Enrolled for Obesity
Marie-France Langlois, MDPrincipal InvestigatorUniversité de Sherbrooke
7 Previous Clinical Trials
1,550 Total Patients Enrolled
4 Trials studying Obesity
1,108 Patients Enrolled for Obesity

Media Library

2-day preceptorship on obesity management Clinical Trial Eligibility Overview. Trial Name: NCT00991640 — N/A
Obesity Research Study Groups: Control, Preceptorships
Obesity Clinical Trial 2023: 2-day preceptorship on obesity management Highlights & Side Effects. Trial Name: NCT00991640 — N/A
2-day preceptorship on obesity management 2023 Treatment Timeline for Medical Study. Trial Name: NCT00991640 — N/A
~29 spots leftby Jul 2025